BRANDICOURT OLIVIER 4

What Happened

• Olivier Brandicourt, a director of Vaxcyte, was granted equity awards on June 15, 2026: 2,194 restricted stock units (RSUs) and 11,034 derivative awards (option-like awards). Both grants were reported at $0 purchase price (awards, not open-market purchases), so no cash changed hands at grant.

Key Details

• Transaction date: June 15, 2026; Form 4 filed June 16, 2026 (within the standard two-business-day reporting window).
• Grants: 2,194 RSUs (reported as shares acquired at $0) and 11,034 derivative awards (reported as acquired at $0).
• Vesting: RSUs convert 1-for-1 to common stock and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to continuous service and potential acceleration (footnote F1). The derivative/option awards vest monthly and fully vest on the same earlier date, subject to continuous service and potential acceleration (footnote F2).
• Shares owned after the transaction: not specified in the information provided.
• No indication of a 10b5-1 plan, tax withholding, or immediate sale in the filing.

Context

• These are grant/award transactions (retention/compensation), not open-market purchases or sales—they don’t reflect an immediate cash outlay by the insider nor an immediate liquidity event. Vesting conditions mean the shares/options are earned over time and depend on continued service (and possible acceleration). For investors, awards are common for executive/director compensation; they’re informative about pay structure but do not on their own signal a buy or sell decision.